Table 1. Asthma model inputs.
Figure 1. Disposition of experience patients for economic model.
Table 2. Lifetime cost effectiveness findings for omalizumab in the Netherlands.
Table 3. Sensitivity analyses for omalizumab in the Netherlands.
Figure 2. Cost effectiveness acceptability curve for omalizumab in the Netherlands.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
